The antiangiogenic monoclonal antibody aflibercept in association with fluorouracil and irinotecan improves the survival of patients with metastatic colorectal cancer (mCRC) treated previously with oxaliplatin-based therapy. Multiple reports raised the hypothesis that the concomitant use of antiresorptive drugs and antiangiogenic drugs may increase the risk of osteonecrosis of the jaw (ONJ). Some reports have been published regarding cases of ONJ during treatment with bevacizumab for mCRC.
Jaw osteonecrosis associated with aflibercept, irinotecan and fluorouracil: attention to oral district
PINTA, Francesco;SPADI, ROSELLA;MECCA, Caterina;ZANINI, Marcello;
2016-01-01
Abstract
The antiangiogenic monoclonal antibody aflibercept in association with fluorouracil and irinotecan improves the survival of patients with metastatic colorectal cancer (mCRC) treated previously with oxaliplatin-based therapy. Multiple reports raised the hypothesis that the concomitant use of antiresorptive drugs and antiangiogenic drugs may increase the risk of osteonecrosis of the jaw (ONJ). Some reports have been published regarding cases of ONJ during treatment with bevacizumab for mCRC.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Jaw osteonecrosis.pdf
Accesso riservato
Tipo di file:
PDF EDITORIALE
Dimensione
579.79 kB
Formato
Adobe PDF
|
579.79 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
